AR068388A1 - Compuesto derivado de imidazol - fenil-oxo-1,4- diazaespiro arilo, su uso para preparar un medicamento, composicion farmaceutica y combinacion que lo comprenden - Google Patents
Compuesto derivado de imidazol - fenil-oxo-1,4- diazaespiro arilo, su uso para preparar un medicamento, composicion farmaceutica y combinacion que lo comprendenInfo
- Publication number
- AR068388A1 AR068388A1 ARP080103909A ARP080103909A AR068388A1 AR 068388 A1 AR068388 A1 AR 068388A1 AR P080103909 A ARP080103909 A AR P080103909A AR P080103909 A ARP080103909 A AR P080103909A AR 068388 A1 AR068388 A1 AR 068388A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- alkyl
- haloalkoxy
- haloalkyl
- halo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 239000011737 fluorine Chemical group 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 abstract 1
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 239000000460 chlorine Chemical group 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuesto de imidazol-fenil-oxo-1,4-diazaespiro arilo, que inhibe el transportador de glicina, de formula (1) o una sal del mismo donde: X es -CH2- u oxigeno; R1, R2, R3 y R4 se seleccionan independientemente entre hidrogeno, alquilo C1-4, alcoxi C1-4, ciano, halo, haloalquilo C1-4, haloalcoxi C1-4, alquiltio C1-4, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-4, cicloalquil C3-6-aIcoxi C1-4, alquilsulfonilo C1-4, alcoxi C1-4-alquilo C1-4 y CONRaRb, donde Ra y Rb se seleccionan independientemente entre hidrogeno y alquilo C1-4, o Ra y Rb, junto con el átomo de nitrogeno al que están unidos forman un anillo de 4 a 7 miembros; o R2 y R3 juntos forman un grupo seleccionado entre -O-CH2-O- y -O-CH2-CH2-O-; R5 se selecciona entre hidrogeno, cloro, fluor, alquilo C1-4 y CF3 uno de R6 y R7 se selecciona entre el grupo que consiste en: hidrogeno, alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, haloalcoxi C1-4, halo, ciano, alcoxi C1-4-alcoxi C1-4 y alcoxi C1-4-alquilo; y el otro se selecciona entre el grupo que consiste en un anillo heteroarilo de 5 a 7 miembros, opcionalmente sustituido con alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, haloalcoxi C1-4, halo o ciano; un anillo heterocíclico, bicíclico, de 9 a 10 miembros, opcionalmente sustituido con alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, haloalcoxi C1-4, halo o ciano; y un anillo heterocíclico de 5 a 7 miembros, opcionalmente sustituido con alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, haloalcoxi C1-4, halo o ciano; o R6 y R7 juntos forman un anillo heterocíclico de 5 a 7 miembros condensado con el anillo de fenilo o un anillo heteroarilo de 5 a 7 miembros condensado con el anillo de fenilo; donde el anillo heterocíclico o el anillo heteroarilo está opcionalmente sustituido con alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, haloalcoxi C1-4, halo o ciano; R15 es hidrogeno o fluor; R8 se selecciona entre hidrogeno y metilo; y m se selecciona entre 0, 1 y 2. Su uso para preparar un medicamento util para tratar trastornos neurologicos y neuropsiquiátricos, en particular psicosis, demencia o trastorno de déficit de atencion. Formulaciones farmacéuticas que lo comprenden.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0717728A GB0717728D0 (en) | 2007-09-11 | 2007-09-11 | Compounds |
| GB0802586A GB0802586D0 (en) | 2008-02-12 | 2008-02-12 | Compounds |
| GB0813501A GB0813501D0 (en) | 2008-07-23 | 2008-07-23 | Pb62624p2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068388A1 true AR068388A1 (es) | 2009-11-11 |
Family
ID=39877729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103909A AR068388A1 (es) | 2007-09-11 | 2008-09-09 | Compuesto derivado de imidazol - fenil-oxo-1,4- diazaespiro arilo, su uso para preparar un medicamento, composicion farmaceutica y combinacion que lo comprenden |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100317704A1 (es) |
| EP (1) | EP2197852A1 (es) |
| JP (1) | JP2010539128A (es) |
| AR (1) | AR068388A1 (es) |
| CL (1) | CL2008002674A1 (es) |
| PE (1) | PE20091091A1 (es) |
| TW (1) | TW200911234A (es) |
| UY (1) | UY31332A1 (es) |
| WO (1) | WO2009034061A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009503006A (ja) * | 2005-08-02 | 2009-01-29 | グラクソ グループ リミテッド | ＧｌｙＴ１トランスポーター阻害剤ならびに神経および神経精神障害の治療におけるその使用 |
| AR059839A1 (es) * | 2006-03-16 | 2008-04-30 | Glaxo Group Ltd | Compuesto derivado de diazaespiro-acetamida, composicion farmaceutica que lo comprende, uso para la preparacion de un medicamento para el tratamiento de un trastorno mediado por glyt1 y proceso para su preparacion |
| US20090326027A1 (en) * | 2006-03-16 | 2009-12-31 | Steven Coulton | N-Phenyl-2-0X0-1,4-Diazaspiro [4.5] Dec-3-EN-1-YL Acetamide Derivatives And Their Use As Glycine Transporter Inhibitors |
| WO2008092872A1 (en) * | 2007-02-01 | 2008-08-07 | Glaxo Group Limited | Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders |
| JP2010517961A (ja) * | 2007-02-01 | 2010-05-27 | グラクソ グループ リミテッド | ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用 |
| JP2010517963A (ja) * | 2007-02-01 | 2010-05-27 | グラクソ グループ リミテッド | 神経学的および神経精神病学的障害の治療におけるＧｌｙＴ１トランスポーター阻害薬としての８−オキサ−１，４−ジアザスピロ［４，５］デク−３−エン−１−イルおよび１，４，８−トリアザスピロ［４，５］デク−３−エン−１−イルアセトアミド誘導体 |
-
2008
- 2008-09-09 UY UY31332A patent/UY31332A1/es unknown
- 2008-09-09 AR ARP080103909A patent/AR068388A1/es not_active Application Discontinuation
- 2008-09-09 TW TW097134474A patent/TW200911234A/zh unknown
- 2008-09-09 PE PE2008001575A patent/PE20091091A1/es not_active Application Discontinuation
- 2008-09-09 CL CL2008002674A patent/CL2008002674A1/es unknown
- 2008-09-09 JP JP2010524470A patent/JP2010539128A/ja active Pending
- 2008-09-09 EP EP08803857A patent/EP2197852A1/en not_active Withdrawn
- 2008-09-09 US US12/676,625 patent/US20100317704A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/061889 patent/WO2009034061A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TW200911234A (en) | 2009-03-16 |
| WO2009034061A1 (en) | 2009-03-19 |
| CL2008002674A1 (es) | 2009-10-16 |
| UY31332A1 (es) | 2009-03-31 |
| PE20091091A1 (es) | 2009-08-28 |
| US20100317704A1 (en) | 2010-12-16 |
| EP2197852A1 (en) | 2010-06-23 |
| JP2010539128A (ja) | 2010-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| TW200800945A (en) | Macrocylic inhibitors of hepatitis c virus | |
| CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| AR061815A1 (es) | Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| EA200800484A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| AR064635A1 (es) | Derivados de benzotiazolona | |
| AR086254A1 (es) | Derivados de imidazol utiles para el tratamiento de artritis | |
| AR087196A1 (es) | Metodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales ii | |
| AR070221A1 (es) | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. | |
| AR065556A1 (es) | Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida | |
| PE20170682A1 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias | |
| AR065300A1 (es) | Compuestos quimicos derivados de 1,2-pirazol | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| PE20141974A1 (es) | Compuestos de heterociclilo | |
| AR046996A1 (es) | Derivados de amino-pirimidinas | |
| AR030306A1 (es) | Derivados de piperazina, un procedimiento para su preparacion, composiciones farmaceuticas, un metodo para su fabricacion y el uso de dichos derivados para la fabricacion de un medicamento | |
| AR065824A1 (es) | Sulfonilbenzamidas sustituidas con heterociclos bloqueantes de los canales de sodio,formulaciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del dolor y particularmente del dolor cronico. | |
| AR071203A1 (es) | Compuesto de trifluorometil-indol-carboxamida, su uso para la fabricacion de un medicamento util para el tratamiento de un trastorno psicotico o deterioro cognitivo y composicion farmaceutica que lo comprende | |
| PE20141582A1 (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| AR059839A1 (es) | Compuesto derivado de diazaespiro-acetamida, composicion farmaceutica que lo comprende, uso para la preparacion de un medicamento para el tratamiento de un trastorno mediado por glyt1 y proceso para su preparacion | |
| ATE500251T1 (de) | Benzimidazole und ihre verwendung zur behandlung von diabetes | |
| AR067075A1 (es) | Derivados de isoxasol - imidazol | |
| AR077227A1 (es) | Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende | |
| PE20090655A1 (es) | Derivados de 2-aza-biciclo[2.2.2]octano para prevencion o tratamiento de psicosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |